Resolys Bio’s multi-component complex (MCC) was originally conceived as a non-opioid therapy to focus on painful tissue-based autoimmune conditions that affect the connective or muscle tissue in diseases such as Joint Hypermobility Syndromes, lupus, and rheumatoid arthritis. MCC is an important example of the Company’s strategy for dealing with chronic conditions by choosing molecules, naturally occurring or FDA approved, that upregulate or downregulate the appropriate genes.
Hypermobility Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder caused by defects in a person’s collagen. Although thought to be a genetic condition, the exact cause is unknown and there are no known treatments specifically for the pain and fatigue associated with hEDS. With no available therapy for hEDS, physicians hypothesize that the pain and fatigue of hEDS may also have an autoimmune component and requested MCC for a small number of patients.
MCC is comprised of very low concentrations of repurposed biological molecules known to physicians and regulators. The mixture of components is believed to act synergistically in ameliorating the pain and fatigue symptoms of hEDS. MCC appears to reverse symptoms but does not modify the proposed underlying genetic causes.
Preliminary, uncontrolled human experience has indicated that patients may experience a meaningful reduction in pain and fatigue within 30 days of treatment with MCC. In recent months evidence has emerged that it may also enhance connective tissue structure, and these improvements may play a role in reducing the symptoms associated with hEDS.